Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics
Purpose Although 221 Fr and 213 Bi have sufficient gamma emission probabilities, quantitative SPECT after [ 225 Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore, 221 Fr and 213 Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2024-07, Vol.51 (8), p.2504-2514 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2514 |
|---|---|
| container_issue | 8 |
| container_start_page | 2504 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 51 |
| creator | Liubchenko, Grigory Böning, Guido Zacherl, Mathias Rumiantcev, Mikhail Unterrainer, Lena M. Gildehaus, Franz Josef Brendel, Matthias Resch, Sandra Bartenstein, Peter Ziegler, Sibylle I. Delker, Astrid |
| description | Purpose
Although
221
Fr and
213
Bi have sufficient gamma emission probabilities, quantitative SPECT after [
225
Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore,
221
Fr and
213
Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted a quantitative SPECT study and a urine analysis to investigate the pharmacokinetics of
221
Fr and
213
Bi and the impact on image-based lesion and kidney dosimetry.
Methods
Five patients (7.7 ± 0.2 MBq [
225
Ac]Ac-PSMA-I&T) underwent an abdominal SPECT/CT (1 h) at 24 and 48 h (Siemens Symbia T2, high-energy collimator, 440 keV/218 keV (width 20%), 78 keV (width 50%)). Quantitative SPECT was reconstructed using MAP-EM with attenuation and transmission-dependent scatter corrections and resolution modelling. Time-activity curves for kidneys (CT-based) and lesions (80% isocontour 24 h) were fitted mono-exponentially. Urine samples collected along with each SPECT/CT were measured in a gamma counter until secular equilibrium was reached.
Results
Mean kidney and lesion effective half-lives were as follows:
213
Bi, 27 ± 6/38 ± 10 h;
221
Fr, 24 ± 6/38 ± 11 h; 78 keV, 23 ± 7/39 ± 13 h. The
213
Bi-to-
221
Fr kidney SUV ratio increased by an average of 9% from 24 to 48 h. Urine analysis revealed an increasing
213
Bi-to-
225
Ac ratio (24 h, 0.98 ± 0.15; 48 h, 1.08 ± 0.09). Mean kidney and lesion absorbed doses were 0.17 ± 0.06 and 0.36 ± 0.1
Sv
RBE
=
5
/MBq using
221
Fr and
213
Bi SPECT images, compared to 0.16 ± 0.05/0.18 ± 0.06 and 0.36 ± 0.1/0.38 ± 0.1
Sv
RBE
=
5
/MBq considering either the
221
Fr or
213
Bi SPECT.
Conclusion
SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%. |
| doi_str_mv | 10.1007/s00259-024-06681-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11178588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3068283451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-88f5d4751620ed75eb81fcaa845db350bc3197cd65a73e152e92359b6cc6fdc53</originalsourceid><addsrcrecordid>eNp9kU1rGzEQhkVJaD7_QA9FEOhNiT5Wu9pTMaZtDA4JxD2VILTSyFaaXW2kdcH_vps4cdpLTjMw77zzMg9Cnxg9Z5RWF5lSLmtCeUFoWSpG-Ad0yEpWk4qqem_XV_QAHeV8TylTXNUf0YFQkvFCFYcozFqzBNKYDA67mEMLQ9pgHxP-xbmc2LuJJTe3VxMy-7LAwwqS6TfYdO6px-A92AFHj51ZL1cDJJJ7sMEHi_uVSa2x8XfoYAg2n6B9bx4ynL7UY_Tz-7fF9JLMr3_MppM5sUXBB6KUl66oJCs5BVdJaBTz1hhVSNcISRsrWF1ZV0pTCWCSQ82FrJvS2tI7K8Ux-rr17ddNC85CNyTzoPsUWpM2Opqg_590YaWX8Y9mjFVKKjU6nL04pPi4hjzo-7hO3RhaC1qOLxSFZKOKb1U2xZwT-N0JRvUTH73lo0c--pmP5uPS53_D7VZegYwCsRXkcdQtIb3dfsf2LwCTm90</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3068283451</pqid></control><display><type>article</type><title>Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Liubchenko, Grigory ; Böning, Guido ; Zacherl, Mathias ; Rumiantcev, Mikhail ; Unterrainer, Lena M. ; Gildehaus, Franz Josef ; Brendel, Matthias ; Resch, Sandra ; Bartenstein, Peter ; Ziegler, Sibylle I. ; Delker, Astrid</creator><creatorcontrib>Liubchenko, Grigory ; Böning, Guido ; Zacherl, Mathias ; Rumiantcev, Mikhail ; Unterrainer, Lena M. ; Gildehaus, Franz Josef ; Brendel, Matthias ; Resch, Sandra ; Bartenstein, Peter ; Ziegler, Sibylle I. ; Delker, Astrid</creatorcontrib><description>Purpose
Although
221
Fr and
213
Bi have sufficient gamma emission probabilities, quantitative SPECT after [
225
Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore,
221
Fr and
213
Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted a quantitative SPECT study and a urine analysis to investigate the pharmacokinetics of
221
Fr and
213
Bi and the impact on image-based lesion and kidney dosimetry.
Methods
Five patients (7.7 ± 0.2 MBq [
225
Ac]Ac-PSMA-I&T) underwent an abdominal SPECT/CT (1 h) at 24 and 48 h (Siemens Symbia T2, high-energy collimator, 440 keV/218 keV (width 20%), 78 keV (width 50%)). Quantitative SPECT was reconstructed using MAP-EM with attenuation and transmission-dependent scatter corrections and resolution modelling. Time-activity curves for kidneys (CT-based) and lesions (80% isocontour 24 h) were fitted mono-exponentially. Urine samples collected along with each SPECT/CT were measured in a gamma counter until secular equilibrium was reached.
Results
Mean kidney and lesion effective half-lives were as follows:
213
Bi, 27 ± 6/38 ± 10 h;
221
Fr, 24 ± 6/38 ± 11 h; 78 keV, 23 ± 7/39 ± 13 h. The
213
Bi-to-
221
Fr kidney SUV ratio increased by an average of 9% from 24 to 48 h. Urine analysis revealed an increasing
213
Bi-to-
225
Ac ratio (24 h, 0.98 ± 0.15; 48 h, 1.08 ± 0.09). Mean kidney and lesion absorbed doses were 0.17 ± 0.06 and 0.36 ± 0.1
Sv
RBE
=
5
/MBq using
221
Fr and
213
Bi SPECT images, compared to 0.16 ± 0.05/0.18 ± 0.06 and 0.36 ± 0.1/0.38 ± 0.1
Sv
RBE
=
5
/MBq considering either the
221
Fr or
213
Bi SPECT.
Conclusion
SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-024-06681-2</identifier><identifier>PMID: 38512484</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Actinium - chemistry ; Actinium - pharmacokinetics ; Aged ; Bismuth isotopes ; Cardiology ; Computed tomography ; Dosimeters ; Dosimetry ; Gamma emission ; Glutamate Carboxypeptidase II - metabolism ; Humans ; Imaging ; Kidney - diagnostic imaging ; Kidney - metabolism ; Kidneys ; Lesions ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Middle Aged ; Nuclear Medicine ; Oncology ; Original ; Original Article ; Orthopedics ; Pharmacokinetics ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - radiotherapy ; Radioisotopes - pharmacokinetics ; Radioisotopes - therapeutic use ; Radiology ; Radiometry ; Radiopharmaceuticals - pharmacokinetics ; Single photon emission computed tomography ; Single Photon Emission Computed Tomography Computed Tomography ; Urine</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2024-07, Vol.51 (8), p.2504-2514</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-88f5d4751620ed75eb81fcaa845db350bc3197cd65a73e152e92359b6cc6fdc53</citedby><cites>FETCH-LOGICAL-c442t-88f5d4751620ed75eb81fcaa845db350bc3197cd65a73e152e92359b6cc6fdc53</cites><orcidid>0000-0001-8888-7272</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-024-06681-2$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-024-06681-2$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38512484$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liubchenko, Grigory</creatorcontrib><creatorcontrib>Böning, Guido</creatorcontrib><creatorcontrib>Zacherl, Mathias</creatorcontrib><creatorcontrib>Rumiantcev, Mikhail</creatorcontrib><creatorcontrib>Unterrainer, Lena M.</creatorcontrib><creatorcontrib>Gildehaus, Franz Josef</creatorcontrib><creatorcontrib>Brendel, Matthias</creatorcontrib><creatorcontrib>Resch, Sandra</creatorcontrib><creatorcontrib>Bartenstein, Peter</creatorcontrib><creatorcontrib>Ziegler, Sibylle I.</creatorcontrib><creatorcontrib>Delker, Astrid</creatorcontrib><title>Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Although
221
Fr and
213
Bi have sufficient gamma emission probabilities, quantitative SPECT after [
225
Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore,
221
Fr and
213
Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted a quantitative SPECT study and a urine analysis to investigate the pharmacokinetics of
221
Fr and
213
Bi and the impact on image-based lesion and kidney dosimetry.
Methods
Five patients (7.7 ± 0.2 MBq [
225
Ac]Ac-PSMA-I&T) underwent an abdominal SPECT/CT (1 h) at 24 and 48 h (Siemens Symbia T2, high-energy collimator, 440 keV/218 keV (width 20%), 78 keV (width 50%)). Quantitative SPECT was reconstructed using MAP-EM with attenuation and transmission-dependent scatter corrections and resolution modelling. Time-activity curves for kidneys (CT-based) and lesions (80% isocontour 24 h) were fitted mono-exponentially. Urine samples collected along with each SPECT/CT were measured in a gamma counter until secular equilibrium was reached.
Results
Mean kidney and lesion effective half-lives were as follows:
213
Bi, 27 ± 6/38 ± 10 h;
221
Fr, 24 ± 6/38 ± 11 h; 78 keV, 23 ± 7/39 ± 13 h. The
213
Bi-to-
221
Fr kidney SUV ratio increased by an average of 9% from 24 to 48 h. Urine analysis revealed an increasing
213
Bi-to-
225
Ac ratio (24 h, 0.98 ± 0.15; 48 h, 1.08 ± 0.09). Mean kidney and lesion absorbed doses were 0.17 ± 0.06 and 0.36 ± 0.1
Sv
RBE
=
5
/MBq using
221
Fr and
213
Bi SPECT images, compared to 0.16 ± 0.05/0.18 ± 0.06 and 0.36 ± 0.1/0.38 ± 0.1
Sv
RBE
=
5
/MBq considering either the
221
Fr or
213
Bi SPECT.
Conclusion
SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.</description><subject>Actinium - chemistry</subject><subject>Actinium - pharmacokinetics</subject><subject>Aged</subject><subject>Bismuth isotopes</subject><subject>Cardiology</subject><subject>Computed tomography</subject><subject>Dosimeters</subject><subject>Dosimetry</subject><subject>Gamma emission</subject><subject>Glutamate Carboxypeptidase II - metabolism</subject><subject>Humans</subject><subject>Imaging</subject><subject>Kidney - diagnostic imaging</subject><subject>Kidney - metabolism</subject><subject>Kidneys</subject><subject>Lesions</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Pharmacokinetics</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radioisotopes - pharmacokinetics</subject><subject>Radioisotopes - therapeutic use</subject><subject>Radiology</subject><subject>Radiometry</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Single photon emission computed tomography</subject><subject>Single Photon Emission Computed Tomography Computed Tomography</subject><subject>Urine</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU1rGzEQhkVJaD7_QA9FEOhNiT5Wu9pTMaZtDA4JxD2VILTSyFaaXW2kdcH_vps4cdpLTjMw77zzMg9Cnxg9Z5RWF5lSLmtCeUFoWSpG-Ad0yEpWk4qqem_XV_QAHeV8TylTXNUf0YFQkvFCFYcozFqzBNKYDA67mEMLQ9pgHxP-xbmc2LuJJTe3VxMy-7LAwwqS6TfYdO6px-A92AFHj51ZL1cDJJJ7sMEHi_uVSa2x8XfoYAg2n6B9bx4ynL7UY_Tz-7fF9JLMr3_MppM5sUXBB6KUl66oJCs5BVdJaBTz1hhVSNcISRsrWF1ZV0pTCWCSQ82FrJvS2tI7K8Ux-rr17ddNC85CNyTzoPsUWpM2Opqg_590YaWX8Y9mjFVKKjU6nL04pPi4hjzo-7hO3RhaC1qOLxSFZKOKb1U2xZwT-N0JRvUTH73lo0c--pmP5uPS53_D7VZegYwCsRXkcdQtIb3dfsf2LwCTm90</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Liubchenko, Grigory</creator><creator>Böning, Guido</creator><creator>Zacherl, Mathias</creator><creator>Rumiantcev, Mikhail</creator><creator>Unterrainer, Lena M.</creator><creator>Gildehaus, Franz Josef</creator><creator>Brendel, Matthias</creator><creator>Resch, Sandra</creator><creator>Bartenstein, Peter</creator><creator>Ziegler, Sibylle I.</creator><creator>Delker, Astrid</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8888-7272</orcidid></search><sort><creationdate>20240701</creationdate><title>Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics</title><author>Liubchenko, Grigory ; Böning, Guido ; Zacherl, Mathias ; Rumiantcev, Mikhail ; Unterrainer, Lena M. ; Gildehaus, Franz Josef ; Brendel, Matthias ; Resch, Sandra ; Bartenstein, Peter ; Ziegler, Sibylle I. ; Delker, Astrid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-88f5d4751620ed75eb81fcaa845db350bc3197cd65a73e152e92359b6cc6fdc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Actinium - chemistry</topic><topic>Actinium - pharmacokinetics</topic><topic>Aged</topic><topic>Bismuth isotopes</topic><topic>Cardiology</topic><topic>Computed tomography</topic><topic>Dosimeters</topic><topic>Dosimetry</topic><topic>Gamma emission</topic><topic>Glutamate Carboxypeptidase II - metabolism</topic><topic>Humans</topic><topic>Imaging</topic><topic>Kidney - diagnostic imaging</topic><topic>Kidney - metabolism</topic><topic>Kidneys</topic><topic>Lesions</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Pharmacokinetics</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radioisotopes - pharmacokinetics</topic><topic>Radioisotopes - therapeutic use</topic><topic>Radiology</topic><topic>Radiometry</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Single photon emission computed tomography</topic><topic>Single Photon Emission Computed Tomography Computed Tomography</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liubchenko, Grigory</creatorcontrib><creatorcontrib>Böning, Guido</creatorcontrib><creatorcontrib>Zacherl, Mathias</creatorcontrib><creatorcontrib>Rumiantcev, Mikhail</creatorcontrib><creatorcontrib>Unterrainer, Lena M.</creatorcontrib><creatorcontrib>Gildehaus, Franz Josef</creatorcontrib><creatorcontrib>Brendel, Matthias</creatorcontrib><creatorcontrib>Resch, Sandra</creatorcontrib><creatorcontrib>Bartenstein, Peter</creatorcontrib><creatorcontrib>Ziegler, Sibylle I.</creatorcontrib><creatorcontrib>Delker, Astrid</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liubchenko, Grigory</au><au>Böning, Guido</au><au>Zacherl, Mathias</au><au>Rumiantcev, Mikhail</au><au>Unterrainer, Lena M.</au><au>Gildehaus, Franz Josef</au><au>Brendel, Matthias</au><au>Resch, Sandra</au><au>Bartenstein, Peter</au><au>Ziegler, Sibylle I.</au><au>Delker, Astrid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>51</volume><issue>8</issue><spage>2504</spage><epage>2514</epage><pages>2504-2514</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Although
221
Fr and
213
Bi have sufficient gamma emission probabilities, quantitative SPECT after [
225
Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore,
221
Fr and
213
Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted a quantitative SPECT study and a urine analysis to investigate the pharmacokinetics of
221
Fr and
213
Bi and the impact on image-based lesion and kidney dosimetry.
Methods
Five patients (7.7 ± 0.2 MBq [
225
Ac]Ac-PSMA-I&T) underwent an abdominal SPECT/CT (1 h) at 24 and 48 h (Siemens Symbia T2, high-energy collimator, 440 keV/218 keV (width 20%), 78 keV (width 50%)). Quantitative SPECT was reconstructed using MAP-EM with attenuation and transmission-dependent scatter corrections and resolution modelling. Time-activity curves for kidneys (CT-based) and lesions (80% isocontour 24 h) were fitted mono-exponentially. Urine samples collected along with each SPECT/CT were measured in a gamma counter until secular equilibrium was reached.
Results
Mean kidney and lesion effective half-lives were as follows:
213
Bi, 27 ± 6/38 ± 10 h;
221
Fr, 24 ± 6/38 ± 11 h; 78 keV, 23 ± 7/39 ± 13 h. The
213
Bi-to-
221
Fr kidney SUV ratio increased by an average of 9% from 24 to 48 h. Urine analysis revealed an increasing
213
Bi-to-
225
Ac ratio (24 h, 0.98 ± 0.15; 48 h, 1.08 ± 0.09). Mean kidney and lesion absorbed doses were 0.17 ± 0.06 and 0.36 ± 0.1
Sv
RBE
=
5
/MBq using
221
Fr and
213
Bi SPECT images, compared to 0.16 ± 0.05/0.18 ± 0.06 and 0.36 ± 0.1/0.38 ± 0.1
Sv
RBE
=
5
/MBq considering either the
221
Fr or
213
Bi SPECT.
Conclusion
SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38512484</pmid><doi>10.1007/s00259-024-06681-2</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8888-7272</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2024-07, Vol.51 (8), p.2504-2514 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11178588 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Actinium - chemistry Actinium - pharmacokinetics Aged Bismuth isotopes Cardiology Computed tomography Dosimeters Dosimetry Gamma emission Glutamate Carboxypeptidase II - metabolism Humans Imaging Kidney - diagnostic imaging Kidney - metabolism Kidneys Lesions Male Medical imaging Medicine Medicine & Public Health Middle Aged Nuclear Medicine Oncology Original Original Article Orthopedics Pharmacokinetics Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - radiotherapy Radioisotopes - pharmacokinetics Radioisotopes - therapeutic use Radiology Radiometry Radiopharmaceuticals - pharmacokinetics Single photon emission computed tomography Single Photon Emission Computed Tomography Computed Tomography Urine |
| title | Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T12%3A41%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Image-based%20dosimetry%20for%20%5B225Ac%5DAc-PSMA-I&T%20therapy%20and%20the%20effect%20of%20daughter-specific%20pharmacokinetics&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Liubchenko,%20Grigory&rft.date=2024-07-01&rft.volume=51&rft.issue=8&rft.spage=2504&rft.epage=2514&rft.pages=2504-2514&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-024-06681-2&rft_dat=%3Cproquest_pubme%3E3068283451%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3068283451&rft_id=info:pmid/38512484&rfr_iscdi=true |